TP53 and B-cell chronic lymphocytic leukemia: TP53 gene maps within a 17p region frequently lost in CLL patients, and TP53 mutations occur in about 8% of CLL patients; both 17p deletion and TP53 mutation are associated with a poor outcome, and patients with TP53 mutations show resistance to Fludarabine-based chemotherapy [24,66,67].